Table 2.

DLBCL genetic subtypes

Genetic types	Subtypes	Main alterations	COO	Clinical outcome [73–77]
MCD/C5/MYD88		MYD88L265P, CD79B, PIM1, PRMD1, BTG1. CD58	ABC	Bad prognosis
BN2/C1/NOTCH2		BCL6 rear., NOTCH2, BCL10, TNFAIP3, CD70, SPEN, CCND3, UBE2A, DTX1	ABC / GCB	Intermediate prognosis
EZB/C3/BCL2	EZB	BCL2 rear., BCL2, EZH2, CREBBP, IRF8, KMT2D, TNFSR14, EP300. MYC rear	GCB	Good prognosis
	EZB-MYC		DH	Bad prognosis
N1/NEC		NOTCH1	Mostly ABC	Bad prognosis
A53/C2/NEC		TP53, aneuploidy	Mostly ABC	Intermediate prognosis
ST2/C4		SOCS1, TET2 & SGK1, STAT3, NFKBIE, BRAF, CD83	Mostly GCB	Good prognosis

Integration of the genetic subtypes described by Wright [74], Chapuy [75], and Lacy [76] and their relation to the cell-or-origin and patient clinical outcome

COO cell-of-origin; ABC activated B-cell; GCB germinal center B-cell; DH double hit; rear. rearrangement